Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Study finds 22% of psoriasis patients with symptoms of psoriatic arthritis

If you have psoriasis or a family history of psoriasis and you are experiencing joint pain and swelling, you could have psoriatic arthritis, a serious disease that may lead to joint destruction and disability.

13 Oct 2011

Nearly one in four people with psoriasis may have undiagnosed psoriatic arthritis

12 Oct 2011

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

The American College of Rheumatology joins organizations from around the world in celebrating World Arthritis Day. Held every year on October 12, this year's theme is "Move to Improve" - focusing on using physical activity to combat arthritis and rheumatic diseases - such as osteoarthritis, rheumatoid arthritis, lupus, gout and psoriatic arthritis.

12 Oct 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

HealthWell Foundation introduces new lupus fund

The HealthWell Foundation, a nonprofit organization providing financial assistance to insured patients facing a variety of chronic and life-altering illnesses, announces the launch of a new fund supporting treatment for Systemic Lupus Erythematosus (SLE), the most common form of lupus.

22 Sep 2011

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Protalix BioTherapeutics, Inc., announced today that the U.S. Food & Drug Administration (FDA) has accepted for review the resubmission of the taliglucerase alfa New Drug Application (NDA) following the Company's receipt of a Complete Response Letter (CRL) in February 2011.

17 Aug 2011

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while Amgen/Pfizer's Enbrel was the most widely used tumor necrosis factor (TNF)-alpha inhibitor for recently treated psoriatic arthritis patients in the fourth quarter of 2010, Abbott's Humira has superseded Enbrel as an early-line TNF-alpha inhibitor for newly diagnosed psoriatic arthritis patients. Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis.

14 Jul 2011

Study reports high prevalence of vitamin D insufficiency in patients with psoriatic arthritis

New research reports a high prevalence of vitamin D insufficiency and deficiency among patients with psoriatic arthritis. Seasonal variation in vitamin D levels was not observed in patients in southern or northern locations.

11 Jul 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man.

14 Jun 2011

NYU Langone webinar discusses advances in the treatment of RA

Steven Abramson, MD, professor of medicine and director of the rheumatology division at NYU Langone Medical Center, hosted a webinar with colleagues from the medical center for rheumatoid arthritis community bloggers - bringing together, bench, bedside and the blogosphere to discuss advances in the investigation, care, and treatment of RA.

13 Jun 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011